DopaDone Neuro Toolkit
For whom:
Browse topics
Method

Weigh an antidepressant against your whole brain picture

Antidepressants work differently across individuals, so assuming everyone has the same serotonin deficiency under-fits real people. A large long-term study also linked some SSRIs to faster memory loss in people who already had dementia, with a dose-response pattern — a reason for extra caution (and the lowest effective dose) when there's existing brain impairment, not a reason to write the drugs off for everyone.

This page isn't typically flagged for the selected profile — shown because you opened it directly.

Two ideas matter when an antidepressant is on the table. The first is individual variation: brains differ, so a single ‘everyone is serotonin-deficient’ model fits real patients poorly. Choosing a medication against an understanding of your specific picture — history, presentation, what’s actually driving the symptoms — is more likely to land than reaching reflexively for one explanation. This is an argument for individualized assessment, not against medication.

The second is a context-dependent risk. A large 11-year Swedish cohort study of people who already had dementia found that several SSRIs (sertraline, fluoxetine, escitalopram, citalopram) were linked to faster memory loss, and the association showed a dose-response gradient — higher doses tracked with worse decline, which strengthens the case that the exposure, not just confounding, was involved. This is observational (association, not proven causation), and crucially it does not mean antidepressants are ‘always bad.’ It means extra caution is warranted when someone already has brain problems: pre-existing pathology may amplify harms that aren’t present in a healthy brain. The practical upshot is to discuss risks with a prescriber, favour the lowest effective dose rather than escalating reflexively, and not generalise this dementia-specific finding to everyone.

Helps with

Resources & links

1 source

What the research says

Scientific grade verified against the literature. No entries = no direct studies (graded from mechanism/experience).

What the grade means

A A — strongest evidence: meta-analyses or RCTs directly confirm it works (or, for diagnostic tools, strong validation of accuracy).
B B — good evidence: a single RCT, or a strong mechanism with supporting studies.
C C — weak / preliminary: a plausible mechanism, but few direct, controlled tests.
D D — no evidence: theory or isolated anecdotes, no studies.
Applies to: ADHD Autism AuDHD